Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity hikes target price on Plus500

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on online trading services Plus500 from 2,650.0p to 2,764.0p on Wednesday, stating that it expects to see "a bumper Q2" trading performance. Canaccord Genuity said key highlights from the Israeli-founded firm's Q125 trading update were news that total revenue had dropped 5% to $205.8m, with customer income up 4% at $176.3m, while customer trading performance sunk 50% to $15.4m, interest income slipped 8% to $14.1m, and underlying earnings were down 9% at $93.8m.

Encouragingly, however, Canaccord noted that underlying average revenue per user was 7% higher year-on-year at $1,351 and average user acquisition cost was 9% lower at $1,205.

"So, given the relatively weak YoY progress in major KPIs, why was the statement so upbeat and why did it state, 'FY25 results expected to be ahead of market expectations'?," asked Canaccord Genuity.

"Principally, we believe management has been given this confidence based on what we anticipate to be an exceptionally strong Q225, driven by the market turmoil caused by Trump's tariffs," it said.

The Canadian bank, which reiterated its 'hold' rating on the stock, made a number of adjustments to its own forecast assumptions, resulting in CY25 earnings per share being upgraded by 11%, largely driven by an expected improvement in the churn rate to 44%. Conversely, Canaccord cut EPS estimates for CY26 by 13% after reducing its customer acquisition and underlying ARPU assumptions.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.